Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension

Theodoropoulou, Sofia; Ellabban, Abdallah A.; Johnston, Robert L.; Cilliers, Helena; Mohamed, Quresh; Sallam, Ahmed

doi:10.1007/s00417-016-3553-1

Cited by 6 publications

(4 citation statements)

References 25 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, none of the study tried to find out if it varies with geographic region. Most of the previous studies were limited to one region [13,[15][16][17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations—GEODEX-IOP study

Sharma¹,

Kuppermann

Bandello

et al. 2019

Eye

View full text Add to dashboard Cite

Purpose To analyse the intraocular pressure rise after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations. Methods The medical charts of 294 dexamethasone implants between February 2011 and 2017 were reviewed retrospectively. South Asian (India), White (Europe, US and Israel) Latino (Argentina and Brazil) patient data was included in the study. Ocular hypertension (OHT) was defined as intraocular pressure of >25 mmHg or an increase of at least 10 mmHg from baseline. The main indications for treatment were diabetic macular edema (ME) (65.6%), retinal vein occlusion (26.5%), uveitis (7.8%). Results Amongst 294 intravitreal implants, ocular hypertension (>25 mmHg) was recorded in 0, 8 and 9.5% in White, Latino, and South Asian groups, respectively. However, IOP > 20 mmHg was recorded in 14%, 28% and 27% in White, Latino, and South Asian groups, respectively. Incidence of very high IOP (>35 mmHg) was lower in all geographical groups. It was 3% in Latino followed by 2% in South Asian group. Conclusion Latino and South Asian groups have higher IOP rise compared to White population. Most patients with elevated IOP fluctuate between 20-25 mmHg.

show abstract

“…However, none of the study tried to find out if it varies with geographic region. Most of the previous studies were limited to one region [13,[15][16][17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations—GEODEX-IOP study

Sharma¹,

Kuppermann

Bandello

et al. 2019

Eye

View full text Add to dashboard Cite

show abstract

“…However, none of these patients required glaucoma surgery. 17 In another study, Mazzarella et al 18 compared IOP response with IDI in eyes with no history of OHT or glaucoma to those with preexisting glaucoma or OHT at baseline. They found that 59% of eyes in the latter group had increased IOP, with 33% requiring increased topical treatment and 3% undergoing glaucoma incisional surgery.…”

Section: Discussionmentioning

confidence: 99%

“…6 In the REMIDO study, 31% of patients with preexisting glaucoma had demonstrated an IOP spike of $ 25 mmHg after 1 month of IDI treatment compared with 6% without glaucoma. 16 Theodoropoulou et al 17 evaluated 33 patients with preexisting glaucoma or OHT ongoing IDI treatment and found that 51% of patients had increased IOP, of whom, 64% required additional topical therapy while the remaining required oral acetazolamide. However, none of these patients required glaucoma surgery.…”

Section: Discussionmentioning

confidence: 99%

United Kingdom Database Study of Intravitreal Dexamethasone Implant (Ozurdex) for Macular Edema Related to Retinal Vein Occlusion

Soliman

Zarranz‐Ventura

Chakravarthy

et al. 2023

Retina

Self Cite

View full text Add to dashboard Cite

To study the treatment patterns, visual outcomes and safety profile of intravitreal dexamethasone implant (IDI) used for the treatment of macular edema secondary to retinal vein occlusion.Methods: Up to 2 years of routinely collected anonymized data within electronic medical record systems were remotely extracted from 16 centers. The outcome measures include visual outcome, number of injections, and safety measures, including the rate of intraocular pressure (IOP) rise, frequency of IOP-lowering medication usage, and cataract surgery rates.Results: The study included 688 eyes (44.4%) with central retinal vein occlusion and 862 eyes (55.6%) with branch retinal vein occlusion; 1,250 eyes (80.6%) were treatment naive and 28% (275/989) had high IOP or were on IOP-lowering medications before IDI use. It was found that 31% (476) of eyes received two injections, and 11.7% (182) and 3.7% (58) of eyes received three and four injections, respectively. The mean baseline Snellen visual acuity improved from 20/125 to 20/40 after the first injection. The probability of cataract surgery was 15% at 24 months. The proportion of eyes with $10 mmHg change from baseline was higher in phakic (14.2%) compared with pseudophakic eyes (5.4%, P = 0.004). Three eyes required IOP filtering surgery (0.2%). Conclusion:The visual results of IDI in eyes with macular edema secondary to retinal vein occlusion in the real world are comparable to those of clinical trial setting. Increased IOP in eyes with preexisting ocular hypertension or glaucoma can be controlled with additional medical treatment. Intraocular pressure rise with IDI may be more frequent in phakic than in pseudophakic eyes.RETINA 43:679-687, 2023D examethasone implant (Ozurdex, Allergan, Dublin, Ireland) treatment for macular edema (ME) in retinal vein occlusion (RVO) has been shown in clinical trials to be effective. [1][2][3] The pivotal clinical trial, GENEVA, demonstrated that a single 0.7-mg implant was well tolerated and improved both functional and anatomical outcomes in eyes with branch RVO (BRVO) and central RVO (CRVO) with 30% of treated eyes gaining $3 lines of vision. 1 This gain was maintained during the open-label extension of the study for a further 12 months. 2 Intravitreal dexamethasone implant (IDI) for the treatment of ME caused by RVO was approved for use in routine clinical care in the United Kingdom in July 2011. 3

show abstract

“…The results showed a higher incidence of RVO among cases who did not receive topical IOP-lowering medications compared to the medication group ( 29 ). IOP-lowering treatment and close monitoring of IOP in the treatment of macular edema due to RVO, in eyes with pre-existing glaucoma or ocular hypertension are also suggested ( 49 ).…”

Section: Discussionmentioning

confidence: 99%

A narrative review on the association of high intraocular pressure and glaucoma in patients with retinal vein occlusion

Jabbehdari¹,

Yazdanpanah²,

Cantor³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background and Objective: Retinal vein occlusion (RVO) is a major cause of vision loss and elevated intraocular pressure (IOP), high ocular perfusion pressure, and glaucoma are known ophthalmic risk factors for RVO. The aim of this paper is to provide the update on the association and management of high IOP/ glaucoma and RVO.Methods: A literature review was performed in PubMed and Medline until May 2022 utilizing specific keywords and cross-matched reference lists.

show abstract

Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension

Cited by 6 publications

References 25 publications

Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations—GEODEX-IOP study

Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations—GEODEX-IOP study

United Kingdom Database Study of Intravitreal Dexamethasone Implant (Ozurdex) for Macular Edema Related to Retinal Vein Occlusion

A narrative review on the association of high intraocular pressure and glaucoma in patients with retinal vein occlusion

Contact Info

Product

Resources

About